Previous close | 34.60 |
Open | 34.78 |
Bid | 33.59 x 1800 |
Ask | 33.59 x 1000 |
Day's range | 33.42 - 34.78 |
52-week range | 24.94 - 41.39 |
Volume | |
Avg. volume | 388,355 |
Market cap | 2.093B |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter Conference call at 4:30 pm ET today BURNABY, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended De
BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 1, 2023. Conference Call/Webcast Information: Date:Wednesday, March 1, 2023 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Dial-In:(800) 715-9871 or (646) 307-1963 for international cal
BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual SVB Securities Global Biopharma Conference taking place from February 14-16, 2023. Company Fireside Chat Presentation Details:Date:Wednesday, February 15, 2023Time:3:00 pm Eastern Time (12:00 pm Pacific Time)Presenters:Ian Mortimer, President and CEO Sherry Aulin, CFOWebcast:Link to pre-r